Figure 5.
Comparison of the simulated dalbavancin AUC0–120 estimates in pediatric subjects of age 3 months to 18 years using various age-dependent dosing regimens to the distribution of AUC0–120 estimates from the adult, phase 3 program (dalbavancin day 1 dose of 1500 mg). The solid line/shaded area represent median/90% confidence interval of AUC0–120 estimates from the adult, phase 3 program (dalbavancin day 1 dose of 1500 mg).